A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration's adverse event reporting system databases.

Front Immunol · 2026 · PMC12945837 · PMID 41766879

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

A highly significant positive signal was detected in FAERS—infusion site discomfort (ROR 88.81, 95% CI 28.56-276.14).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.